or Try an Advanced Search...

    Technical Analysis for DNTH - Dianthus Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 27.96 0.76% 0.21
    DNTH closed up 0.76 percent on Wednesday, October 30, 2024, on 31 percent of normal volume. It was able to find support at its 50 day moving average.
    Earnings due: Nov 7
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Flat
    Historical DNTH trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    50 DMA Support Bullish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    20 DMA Support Bullish 0.76%
    50 DMA Support Bullish 0.76%
    Bollinger Band Squeeze Range Contraction 0.76%
    NR7 Range Contraction 0.76%
    Crossed Above 50 DMA Bullish -0.57%
    Bollinger Band Squeeze Range Contraction -0.57%
    Inside Day Range Contraction -0.57%
    Older End-of-Day Signals for DNTH ...

       Recent Intraday Alerts

    Alert Time
    Up 2% about 16 hours ago
    10 DMA Resistance about 17 hours ago
    60 Minute Opening Range Breakout about 18 hours ago
    Rose Above Previous Day's High about 18 hours ago
    Rose Above 10 DMA about 18 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    DNTH Chart by TradingView
    Basic chart:

    Profile

    Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs and delivers novel monoclonal antibodies. It develops monoclonal antibodies and complement therapeutics to deliver transformative medicines for patients with rare diseases. Dianthus Therapeutics, Inc. was incorporated in 2019 and is based in Waltham, Massachusetts, with an additional office in New York, New York
    Classification
    Keywords: Biotechnology Immunology Immune System Antibodies Monoclonal Antibody Rare Diseases Antibody

    Is DNTH a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 15 Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
    Oct 8 Dianthus: Modest Opportunity With 2 Caveats
    Oct 3 Dianthus started at outperform by Oppenheimer on DNTH103 opportunity
    Oct 1 Dianthus Therapeutics files $500M mixed shelf offering
    Sep 4 Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
    Aug 10 Dianthus Therapeutics Second Quarter 2024 Earnings: Beats Expectations
    Aug 9 Dianthus Therapeutics GAAP EPS of -$0.51 beats by $0.04
    Aug 8 Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
    Jul 29 Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition
    Jul 26 Baird starts Dianthus at outperform, cites lead drug DNTH103
    See more DNTH news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 33.77
    52 Week Low 6.58
    Average Volume 203,620
    200-Day Moving Average 25.53
    50-Day Moving Average 27.72
    20-Day Moving Average 27.73
    10-Day Moving Average 27.98
    Average True Range 1.46
    RSI (14) 51.22
    ADX 10.56
    +DI 17.57
    -DI 21.43
    Chandelier Exit (Long, 3 ATRs) 25.18
    Chandelier Exit (Short, 3 ATRs) 29.30
    Upper Bollinger Bands 29.20
    Lower Bollinger Band 26.26
    Percent B (%b) 0.58
    BandWidth 10.63
    MACD Line 0.09
    MACD Signal Line 0.07
    MACD Histogram 0.016
    Fundamentals Value
    Market Cap 819.74 Million
    Num Shares 29.3 Million
    EPS -2.91
    Price-to-Earnings (P/E) Ratio -9.61
    Price-to-Sales 147.91
    Price-to-Book 2.94
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 29.19
    Resistance 3 (R3) 29.17 28.75 28.99
    Resistance 2 (R2) 28.75 28.43 28.76 28.92
    Resistance 1 (R1) 28.35 28.24 28.55 28.37 28.85
    Pivot Point 27.93 27.93 28.03 27.94 27.93
    Support 1 (S1) 27.53 27.61 27.73 27.55 27.07
    Support 2 (S2) 27.11 27.42 27.12 27.00
    Support 3 (S3) 26.71 27.11 26.94
    Support 4 (S4) 26.73